As a result, the objective of this study was to research and examine any potential contributions to TMX resistance in BC patients made by the novel mitochondrial and metabolic axis TUG-1, miR-186, SIRT3, PPAR-α, and HIF-1. Here, TUG1 is linked to breast cancer.